华盛顿

我们是谁

  • 4 月 5, 2022
    A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
  • 4 月 5, 2022
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
  • 4 月 5, 2022
    Repotrectinib（TPX-0005）对携带 ALK、ROS1 或 NTRK1-3 基因重排的晚期实体瘤患者的研究
  • 4 月 5, 2022
    TAPUR：测试食品药品管理局（FDA）批准的针对晚期癌症患者肿瘤基因特定异常的药物的使用情况
  • 4 月 5, 2022
    A Study of NX-1607 in Adults With Advanced Malignancies
  • 4 月 5, 2022
    A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
  • 4 月 5, 2022
    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
  • 4 月 5, 2022
    A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
  • 4 月 5, 2022
    CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)